HCPCS J0897: Denosumab Injection, 1 mg
HCPCS Level II code J0897 denotes a 1 mg unit of denosumab administered by injection. Denosumab is a monoclonal antibody therapy used in clinical management of conditions that require inhibition of bone resorption; billing for its units is a common element of oncology, endocrinology, and rheumatology care delivery. Nationally, accurate coding of J0897 matters for drug cost accounting, payer coverage determinations, and claim adjudication due to denosumab’s high per-unit cost and varied indications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0897 represents, payer coverage context, and the types of benchmarks and policy details typically reviewed when evaluating injectable biologic drug codes. The publication presents clinical context about the service type and typical sites of service, common billing modifiers and payer considerations (listed separately), and where to look for relevant policy updates affecting biologic drug reimbursement.
This summary is intended to orient billing managers, revenue cycle leaders, and clinical administrators to the core billing identity of J0897, the payer landscape considered, and the topics addressed in the full publication, including reimbursement benchmarks, prior authorization trends, and coding guidance where available.
Sign up for hcpcs J0897 policy alerts
Get alerted when payer policies referencing J0897 are released or updated.
Billing Code Overview
HCPCS Level II code J0897 represents an injection of denosumab, 1 mg. The code denotes the unit of medication administered for denosumab, a monoclonal antibody used in clinical settings for conditions involving bone resorption.
-
Service type: Drug administration (injectable biologic)
-
Typical site of service: Ambulatory infusion clinic, physician office, hospital outpatient department, or other infusion settings where injectable biologic therapies are delivered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old postmenopausal woman with a history of osteoporosis and a recent fragility wrist fracture presents to the outpatient infusion clinic for administration of denosumab. The patient has dual-energy X-ray absorptiometry (DXA) confirming low bone mineral density and meets criteria for pharmacologic therapy. The clinic verifies allergies, recent calcium and vitamin D supplementation, and current serum calcium level prior to treatment. The registered nurse confirms informed consent and performs medication reconciliation, then prepares and administers the subcutaneous injection of denosumab. The encounter includes medication administration, post-injection observation for adverse reactions, documentation of lot number and dose, and scheduling of the next dose in six months.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological amount discarded | When part of an expensive biologic vial is discarded and payor requires reporting of discarded drug units |
JZ | No drug or biological amount discarded | When the exact billed single-use syringe or vial was fully administered with no waste |
59 | Distinct procedural service | When a separately identifiable injection or service is performed on the same day as another procedure not normally reported together |
25 | Significant, separately identifiable evaluation and management service | When a significant E/M visit is documented on the same day as the injection |
52 | Reduced services | When the administration service was partially reduced or not fully performed for documented clinical reasons |
53 | Discontinued procedure | When the administration was started but cancelled/aborted due to patient reaction or other valid reason |
76 | Repeat procedure or service by same physician | When the injection is repeated by the same provider during the same encounter (rare for this drug) |
62 | Two surgeons | If two providers of different specialties jointly provide services during the same encounter (uncommon for injection) |
AA | Anesthesia services performed personally by anesthesiologist | Not typically used for routine subcutaneous denosumab but applicable if provided under monitored anesthesia care (included for completeness) |
KX | Requirements specified in the medical policy are met | When coverage criteria or medical necessity modifiers are required by the payor policy and documentation supports those criteria |
GA | Waiver of liability statement on file (patient refusal of Medicare-covered services) | When the patient signs an advance beneficiary notice or similar waiver for non-covered service |
GZ | Item or service expected to be denied as not reasonable and necessary | When the provider documents medical necessity but anticipates denial by Medicare |
JW duplicates are intentionally not repeated | Duplicate entry avoidance | Duplicate row removed |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 253E00000X | Endocrinology, Diabetes & Metabolism | Common specialty initiating denosumab for metabolic bone disease management |
| 207RC0000X | Family Medicine | Primary care providers who may prescribe and administer denosumab in office-based settings |
| 208000000X | Internal Medicine | Internists managing osteoporosis and coordinating infusion/administration services |
| 363A00000X | Clinical Nurse Specialist | Advanced practice nurses who often administer and manage biologic injections |
| 207K00000X | Obstetrics & Gynecology | Gynecologists may treat postmenopausal osteoporosis and arrange administration |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M81.0 | Age-related osteoporosis without current pathological fracture | Common indication for denosumab to increase bone mass and reduce fracture risk in older adults |
M80.0X1 | Age-related osteoporosis with current pathological fracture, vertebra | Denosumab may be used in patients with osteoporosis and recent fragility fracture to reduce further fracture risk |
M81.8 | Other osteoporosis without current pathological fracture | Used when a specific subtype is not coded but osteoporosis treatment is indicated |
Z79.51 | Long-term (current) use of bisphosphonates | Documentation of prior osteoporosis therapy; denosumab may be used when bisphosphonates are contraindicated or not tolerated |
Z46.89 | Encounter for other specified therapeutic devices and supplies | Administrative code occasionally used when documenting ongoing therapy coordination and supply needs (ancillary relevance) |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96401 | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | Sometimes billed for complex subcutaneous biologic injections when local or payor rules require an administration code for injectable biologics (verify payor policy) |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Commonly used for reporting the professional administration service for a single subcutaneous injection like denosumab in an office setting |
99070 | Supplies and materials provided by the physician over and above those usually included with the office visit | Used to report separately billed supplies associated with injection administration when allowed by payor |
96360 | Intravenous infusion, hydration; initial, 31 minutes to 60 minutes | Not directly related but may appear if the patient required IV therapy for an adverse event during the visit |
99213 | Office or other outpatient visit for the evaluation and management of an established patient, moderate severity | Common E/M code for pre-injection assessment, counseling, and follow-up planning when a significant E/M service is documented on the same day |